Even though the precise functional roles of the downregulated biomarkers in CLN2 disease subjects’ CSF is yet unclear, their identities have previously been associated with neurological disorders and thus may offer insight into TPP1 deficiency as a metabolic disease. This evidence concerns the gene TPP1 and nervous system disorder.